Montefiore Einstein Comprehensive Cancer Center | Strategic Alliance Partners

November 07, 2024

Sheldon M. Feldman, MD, discusses the recognition of racial disparities in breast cancer, as well as the mitigation of treatment-related toxicities.

November 07, 2024

Sheldon M. Feldman, MD, discusses the significance of the new classification of HER2-low breast cancer and how this affects HER2+ breast cancer treatment

October 31, 2024

Sheldon M. Feldman, MD, discusses disparities, post-treatment care, and technological advancements in breast cancer during Breast Cancer Awareness Month.

October 30, 2024

Sheldon M. Feldman, MD, discusses the importance of personalized medicine in breast cancer during Breast Cancer Awareness Month.

October 29, 2024

Sheldon M. Feldman, MD, discusses how the use of personalized medicine has evolved in breast cancer management.

October 28, 2024

Sheldon M. Feldman, MD, discusses the importance of Breast Cancer Awareness Month as well as timely screening and early detection.

October 03, 2024

Drs Patel and Stiles discuss the significance of the FDA approval of perioperative durvalumab for patients with resectable non–small cell lung cancer.

August 15, 2024

Brendon M. Stiles, MD, discusses the FDA approval of perioperative durvalumab plus chemotherapy in early-stage non–small cell lung cancer.

August 05, 2024

Dr Halmos discusses common AEs associated with the ADCs that are used in NSCLC and ways to manage and mitigate these toxicities.

May 20, 2024

Radiation therapy is a critical component of cancer care that is currently being used in approximately 50% of all patients with cancer.

April 06, 2024

Neel P. Chudgar, MD, discusses his presentation on resectability in non–small cell lung cancer at the 21st Annual Winter Lung Cancer Conference®.

April 02, 2024

As genomic testing becomes ubiquitous in cancer care, some patients experience out-of-pocket costs that may affect oncologists’ genetic testing decisions.

April 01, 2024

Neel P. Chudgar, MD, discusses considerations for determining lung cancer resection eligibility and how neoadjuvant therapy may affect resectability.

March 11, 2024

Neel P. Chudgar, MD, discusses the nuances of defining resectability in patients with non–small cell lung cancer.

February 07, 2024

Balazs Halmos, MD, discusses the FLAURA2 and MARIPOSA trials of EGFR TKIs plus chemotherapy in EGFR-mutated non–small cell lung cancer.

February 06, 2024

Investigators evaluated risk factor–based guidelines and risk model–based strategies for lung cancer screening in World Trade Center–exposed responders.

February 04, 2024

Balazs Halmos, MD, discusses treatment strategies for patients with EGFR-mutant non–small cell lung cancer.

January 18, 2024

Genetic screening and testing have only recently become an integral part of cancer care.

January 08, 2024

Drs Donington and Stiles discuss the implications of perioperative immunotherapy trials on early-stage lung cancer management, definitions of resectability, and the incorporation of new multidisciplinary management guidance.

December 15, 2023

Leading researchers in rare blood cancers to investigate new therapeutic strategy that targets leukemic stem cells.